Ahmed Allam Mohamed

Dr. Ahmed Allam Mohamed

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2025 in Clinical Oral Investigations
Verified
Journal Article
Open access
PDF file
JLJulian Leeder
Julian Leeder
AMAli Modabber
Ali Modabber
FHFrank Hölzle
Frank Hölzle
MEMichael J. Eble
Michael J. Eble
AMAhmed Allam Mohamed
Ahmed Allam Mohamed
Introduction: Mandibular osteoradionecrosis (ORN) is a serious complication of radiotherapy (RT) for head and neck cancer (HNC), with an incidence of 3–15%. ORN results from radiation-induced bone necrosis and may require surgical intervention. This study investigates clinical and dosimetric predictors of ORN risk and develops a predictive model for individualized risk assessment. Materials and methods: This retrospective case-control study included 298 HNC patients treated with RT or chemoradiotherapy between January 2012 and May 2020. Dosimetric parameters, including mandibular V10–V60, mean dose (Dmean), and maximum dose (Dmax), were analyzed alongside clinical data such as age, tumor site, smoking history, and dental extractions. Results: Over a median follow-up of 32.4 months, 20 patients (6.7%) developed ORN, with a 5-year cumulative incidence of 7.4%. Multivariate analysis identified mandibular V50 (HR = 1.05, p = 0.0015) and post-RT dental extractions (HR = 2.51, p < 0.0001) as significant ORN risk factors, while age was protective (HR = 0.96, p = 0.047). A V50 cutoff of 25.4 cm³ was most predictive (p = 0.0016). The multivariate model incorporating V50, age, and dental extractions demonstrated strong accuracy (C-index: 0.815, AUC: 0.8). Conclusion: V50 and post-RT dental extractions are key predictors of ORN. The developed nomogram enables personalized risk assessment, supporting treatment optimization. These findings emphasize the need for tailored RT planning and dental care to mitigate ORN risk, warranting validation in multi-institutional cohorts.

8 December 2023 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
AMAhmed Allam Mohamed
Ahmed Allam Mohamed
MGMiguel Goncalves
Miguel Goncalves
BSBiney Pal Singh
Biney Pal Singh
MTMareike Tometten
Mareike Tometten
ARAshkan Rashad
Ashkan Rashad
MEMichael Eble
Michael Eble
Introduction: Oligometastatic disease (OMD) is a metastatic stage that could benefit maximally from local therapies. Patients in this state have a better prognosis relative to those with disseminated metastases. Stereotactic radiotherapy provides a non-invasive ablative tool for primary malignant tumors and metastases. Materials and methods: We searched our register for patients with oligometastatic or recurrent head and neck cancer (OMD/R-HNC) who received stereotactic radiotherapy to manage their OMD/R. We evaluated the survival outcomes and prognostic factors that affected the survival of those patients. Results: In all, 31 patients with 48 lesions met the inclusion criteria for the analysis. The lesions comprised various metastatic sites, with the majority being pulmonary (37 lesions). Squamous cell cancer was the most common histology (26 patients). The median overall survival (mOS) was 33 months, with a progression-free survival (PFS) of 9.6 months. Eight patients received subsequent stereotactic radiotherapy after disease progression. The local control (LC) rates were 91.3, 87.7, and 83% at 6, 12, and 36 months. Patients with the de novo OMD who received stereotactic radiotherapy as their initial treatment had a median systemic treatment-free survival of 23.9 months. In univariate analysis, a trend for better OS was observed in patients with p16-positive squamous cell tumors; patients who progressed within 150 days after diagnosis had a significantly lower OS. De novo OMD showed significantly better PFS compared to induced OMD. Multivariate analyses identified p16-positive squamous cell cancer, metachronous OMD and a longer time to progression as positive predictors of OS, while de novo OMD was the only positive predictor for PFS. Treatment-related toxicities were generally mild, with two cases of grade 3 dysphagia reported. Conclusion: Stereotactic radiotherapy demonstrated favorable outcomes in patients with OMD/R-HNC with limited toxicities. Further studies are warranted to validate these findings and optimize treatment strategies for this patient population.

18 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AMAhmed Allam Mohamed
Ahmed Allam Mohamed
KRKathrin Risse
Kathrin Risse
JSJennifer Stock
Jennifer Stock
AHAlexander Heinzel
Alexander Heinzel
FMFelix M. Mottaghy
Felix M. Mottaghy
MEMichael Johannes Eble
Michael Johannes Eble
Background and aim: Sarcopenia and body composition parameters such as visceral and subcutaneous adipose tissue and visceral-to-subcutaneous adipose tissue ratio have been shown to be relevant biomarkers for prognosis in patients with different types of cancer. However, these findings have not been well studied in anal cancer to date. Therefore, the aim of this study was to evaluate the prognostic value of different body composition parameters in patients undergoing radiation therapy for the treatment of anal cancer with curative intent. Material and Methods: After approval by the institutional ethical committee, we retrospectively identified 81 patients in our local registry, who received radical intensity-modulated radiotherapy for the management of anal squamous cell cancer (ASCC). Clinical information, including body mass index (BMI), survival, and toxicities outcome, were retrieved from the local hospital registry. Based on the pre-therapeutic computer tomography (CT), we measured the total psoas muscle area, visceral adipose tissue area (VAT), subcutaneous adipose tissue area (SAT), and visceral-to-subcutaneous adipose tissue area ratio (VSR). In addition to the classical prognostic factors as T-stage, N-stage, gender, and treatment duration, we analyzed the impact of body composition on the prognosis in univariate and multivariate analyses. Results: Sarcopenia was not associated with increased mortality in anal cancer patients, whereas increased BMI (≥27 kg/m2) and VSR (≥0.45) were significantly associated with worsened overall survival and cancer-specific survival in both univariate and multivariate analyses. VSR—not BMI—was statistically higher in males. Sarcopenia and VSR ≥ 0.45 were associated with advanced T-stages. None of the body composition parameters resulted in a significant increase in treatment-related toxicities. Conclusion: BMI and visceral adiposity are independent prognostic factors for the survival of patients with anal cancer. Measurements to treat adiposity at the time of diagnosis may be needed to improve the survival outcomes for the affected patients.

5 February 2024 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
AMAhmed Allam Mohamed
Ahmed Allam Mohamed
MDMelina Nausikaa Douglas
Melina Nausikaa Douglas
PBPhilipp Bruners
Philipp Bruners
MEMichael J. Eble
Michael J. Eble
Background: Radiotherapy is one of the main treatment options for patients with esophageal cancer; however, it has been linked with an increased risk of cardiac toxicities. In the current study, we evaluated the effect of planning the radiation in deep-inspiration breath hold (DIBH) on the dose sparing of cardiac substructures and lung. Materials and methods: In this study, we analyzed 30 radiation therapy plans from 15 patients diagnosed with esophageal cancer planned for neoadjuvant radiotherapy. Radiation plans were generated for 41.4 Gy and delivered in 1.8 Gy per fraction for free-breathing (FB) and DIBH techniques. We then conducted a comparative dosimetric analysis, evaluating target volume coverage, the impact on cardiac substructures, and lung doses across the two planning techniques for each patient. Results: There was no significant disparity in target volume dose coverage between DIBH and FB plans. However, the Dmean, D2%, and V30% of the heart experienced substantial reductions in DIBH relative to FB, with values of 6.21 versus 7.02 Gy (p = 0.011), 35.28 versus 35.84 Gy (p = 0.047), and 5% versus 5.8% (p = 0.048), respectively. The Dmean of the left ventricle was notably lower in DIBH compared to FB (4.27 vs. 5.12 Gy, p = 0.0018), accompanied by significant improvements in V10. Additionally, the Dmean and D2% of the left coronary artery, as well as the D2% of the right coronary artery, were significantly lower in DIBH. The dosimetric impact of DIBH on cardiac substructures proved more advantageous for middle esophageal (ME) than distal esophageal (DE) tumors. Conclusion: Radiotherapy in DIBH could provide a method to reduce the radiation dose to the left ventricle and coronaries, which could reduce the cardiac toxicity of the modality.

12 November 2024 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
AMAhmed Allam Mohamed
Ahmed Allam Mohamed
CSCennet Sahin
Cennet Sahin
MBMarie-Luise Berres
Marie-Luise Berres
OBOliver Beetz
Oliver Beetz
MWMartin von Websky
Martin von Websky
MEMichael J. Eble
Michael J. Eble
Hepatocellular carcinoma (HCC) poses a significant challenge for patients ineligible for surgical resection or liver transplantation. Local therapies like Stereotactic Body Radiotherapy (SBRT) are crucial for those with liver-limited disease. Insulin-like growth factor-1 (IGF-1) is a potential biomarker for liver function. This study evaluates IGF-1’s prognostic value in predicting survival outcomes in HCC patients undergoing SBRT. We analyzed 42 HCC patients treated with SBRT between May 2021 and January 2024, with IGF-1 levels measured within four weeks before SBRT. Patient demographics, tumor metrics, and clinical outcomes were examined. The prognostic significance of IGF-1 was assessed using Cox proportional hazards and ROC curve analysis to determine optimal IGF-1 cutoffs for survival prediction. A nomogram predicting 1-year and 2-year survival was constructed using a multivariate Cox model. IGF-1 levels were significantly lower in patients with cirrhosis or sarcopenia. Median overall survival (OS) was 24 months, with a significant survival difference favoring patients with IGF-1 levels above 62.4 ng/ml (Hazard Ratio [HR]: 5.9, P = 0.0025). A multivariable Cox model including Child-Turcotte-Pugh (CTP) score, IGF-1, and tumor volume effectively predicted survival. IGF-1 and tumor volume significantly impacted OS (HR: 6.9 and 1.004, p = 0.014 and 0.0022, respectively). Integrating IGF-1 with CTP score improved predictive accuracy (c-index 0.66 to 0.75, p = 0.052). The nomogram, integrating IGF-1 with the CTP and tumour volume, exhibited robust predictive accuracy with an area under the curve (AUC) of 0.84 for 2-year survival. IGF-1 is a reliable biomarker for liver function and survival prediction in HCC patients undergoing SBRT. Higher IGF-1 levels indicate better prognosis. The developed nomogram, incorporating IGF-1, enhances clinical decision-making for SBRT management. Further validation in larger cohorts is needed.

26 May 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
AMAhmed Allam Mohamed
Ahmed Allam Mohamed
MSMarsha Schlenter
Marsha Schlenter
AHAlexander Heinzel
Alexander Heinzel
SKSvetlana Kintsler
Svetlana Kintsler
MEMichael J. Eble
Michael J. Eble
Purpose: To describe the survival and toxicity outcome from a single-centre experience in patients with squamous cell cancer of the anal canal (SCC-AC), related to the impact of technological advances in diagnostics and radiation techniques. Material and Methods: A retrospective cohort study was performed after the approval of the institutional ethical committee (EK 478-21). We identified 142 patients in our registry, who received radical treatment for SCC-AC between 2000 and 2020. Fifty-five patients had FDG PET/CT for initial staging and target volume delineation, 87.33% received concomitant chemoradiotherapy (CRT), 64 patients were treated with 3-dimensional conformal radiotherapy (3DRT) between 2000-2009, and 78 patients with intensity-modulated radiotherapy (IMRT) between 2009-2020. Endpoints for the analysis included locoregional relapse-free survival (LRFS), disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS). Acute and late toxicities were also reported. Results: At a median follow-up of 31.2 months, the median overall survival was 135 months, 5-year LRFS was 73.1%, 5-year DFS was 65.3%, and 5-year CSS was 75.3%. The use of IMRT was associated with shorter treatment duration. In the univariate analysis, IMRT was associated with significantly improved DFS and CSS for the whole cohort and significantly improved DFS, OS, and CSS for patients who received CRT. In the multivariate analysis, IMRT was associated with the improvement of all survival paraments. The use of FDG PET/CT did not translate into an improvement in the survival outcomes in both univariate and multivariate analyses. Grade-3 and more dermatological toxicities occurred less frequently, but hematological toxicities were more frequent in the IMRT-group. Late side effects and colostomies were less frequently reported in the IMRT group. Conclusion: The use of IMRT in the management of SCC-AC was associated with improvement of the oncological outcomes with improved toxicity profiles in this long-term single-centre experience.